Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBIT Margin (2020 - 2025)

GeneDx Holdings (WGS) has disclosed EBIT Margin for 6 consecutive years, with 11.77% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 2097.0% to 11.77% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.06%, a 454.0% increase, with the full-year FY2025 number at 3.06%, up 454.0% from a year prior.
  • EBIT Margin was 11.77% for Q4 2025 at GeneDx Holdings, down from 2.78% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 6294.74% in Q2 2021 to a low of 529.56% in Q4 2022.
  • A 5-year average of 195.49% and a median of 62.63% in 2023 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: crashed -674443bps in 2022, then surged 48489bps in 2023.
  • GeneDx Holdings' EBIT Margin stood at 200.31% in 2021, then tumbled by -164bps to 529.56% in 2022, then skyrocketed by 92bps to 44.66% in 2023, then soared by 121bps to 9.21% in 2024, then tumbled by -228bps to 11.77% in 2025.
  • Per Business Quant, the three most recent readings for WGS's EBIT Margin are 11.77% (Q4 2025), 2.78% (Q3 2025), and 8.73% (Q2 2025).